Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PYC Therapeutics Limited ( (AU:PYC) ) has issued an update.
PYC Therapeutics Limited announced a change in the director’s interest as Dr. Rohan Hockings acquired 133,350 ordinary shares through an on-market purchase valued at $200,003. This acquisition reflects a significant personal investment by the director, potentially indicating confidence in the company’s future prospects and strategic direction.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited operates in the biotechnology industry, focusing on the development of precision medicines. The company is engaged in creating therapies that target genetic disorders, leveraging their expertise in RNA therapeutics to address unmet medical needs.
Average Trading Volume: 728,826
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$819.5M
See more data about PYC stock on TipRanks’ Stock Analysis page.